Partnership to Develop Urea Cycle Disorders Therapy

Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders  Boehringer Ingelheim will be commencing a new collaboration with Thoeris GmbH with the goal of advancing a first-in-class approach for the treatment of urea cycle disorders (UCDs) independent of the underlying monogenetic causeUCDs are genetic disorders with highly variable onset and severity, causing excess ammonia levels in the blood, which can lead to irreversible brain damage, coma and deathThis collaboration is part of Boehringer Ingelheim ’s commitment to leveraging emerging science to deliver transformative treatment options for patients with high medical need.
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news